DISORDERS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative tumor disease of the hematopoietic tissue, which is based on the polyclonal proliferation of B-lymphocytes with a specific immunophenotype. Due to the frequent infectious diseases, which take place in such patients the investigation of immunity is very important. Aim of research. The purpose of the work was to determine the immunological characteristics of patients with B-CLL before the start of chemotherapeutic treatment and after blocks of chemotherapy. Materials and methods. To perform the work, a clinical and laboratory examination of patients for the first time diagnosed B-CLL II (B) - III (C) stages was conducted. Results of the research. It was found that in pa-tients with B-CLL before treatment by protocol with using of fludarabin and cyclophosphamide significantly lower levels of CD3+, CD4+, SD16+, CD22+ cells, im-munoglobulins, circulating immune complexes and phag-ocytosis were observed compared to individuals in the control group. This immune dysfunction is the reason of the development of infectious diseases in B-CLL patients. Based on the results of the study, positive immunomodu-latory effect of etiopathogenetical treatment on serum immunoglobulins, subpopulations of lymphocytes and phagocytic function parameters was found. However, the presence of frequent infectious syndrome in patients shows that quantitative indicators immunogram im-provements are not sufficient to ensure adequate im-mune defense against infections, which may be associated with morphological changes in the structure of antibodies and immune cells structure. Conclusions. The established changes in the complex immunological examination in patients with B-CLL before etiopathogenetic treatment were significantly more pronounced than in patients after the completion of chemotherapy cycles. Comprehensive chemotherapy with the use of fludarabine and cyclophosphamide positively affects the normalization of cellular, humoral immunity, and phagocytosis. However, the presence of frequent infectious syndrome in patients with B-CLL indicates the need for further research on immune protection to create a treatment algorithm.